Generic drug sales increased 20 percent and sales of the anesthetic Lidoderm increased 16 percent. Stocks ended at $1.27 per share, above expectations of $1.18 per share.
Lower expectations were due in part to two patent lawsuit settlements.
More Articles on Anesthesia:
First Grad Completes TeamHealth Anesthesia Management Fellowship
Colorado Court Says CRNAs Can Administer Anesthesia
Somnia Releases White Paper on Anesthesia’s Role in Perioperative Management
Register to Attend Webinar
Presenters:
James Germano, MD, Joint Reconstruction Specialist|Tim Tzimas, Innovative Sterilization Technologies
Next Up in Financial Management
-
Forty states and Puerto Rico have signed agreements to join the Generous Model, a Medicaid drug payment initiative that ties…
-
Four revenue cycle leaders at the Becker’s 11th Annual Health IT + Digital Health + RCM Conference are shedding light…
-
Leadership succession is ultimately about protecting an organization’s mission rather than any individual’s tenure, Rick Pollack, retiring president and CEO…
Join the 500,000+ healthcare executives who start their day with Becker's
Becker's Hospital Review Newsletter is sent Monday–Sunday.
